- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02421328
Study of the Effects of CPAP and HHHFNC on Diaphragmatic Dimensions in Preterm Infants
Comparative Study of the Effects of Continuous Positive Airway Pressure and Heated, Humidified High Flow Nasal Cannula on Diaphragmatic Dimensions in Preterm Infants
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Preterm infants will be recruited consecutively from NICU of Mansoura University Children's Hospital. They will be randomized in two groups; one group will start on nasal CPAP (Fisher & Paykel Healthcare, Auckland, New Z ealand) (Pressure 5 cmH2O) for 60 minutes and then will be switched to HHHFNC (Fisher & Paykel Healthcare, Auckland, New Z ealand) (flow of 4 l/m) for another 60 minutes. The other group will start on HHHFNC and then switched to nasal CPAP.
After the 2 h study period (2×60 minutes epochs) further respiratory support will be at the discretion of the clinical team.
Ultrasonographic assessment of diaphragmatic dimensions and excursion will be analyzed in different respiratory cycles and the average of 3 cycles will be calculated at the end of the 60 minutes periods on nasal CPAP and HHHFNC.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Dakahlia
-
Mansoura, Dakahlia, Egypte, 35516
- Neonatal Intensive Care Unit, Mansoura University Children Hospital
-
Mansoura, Dakahlia, Egypte, 35516
- NICU, Mansoura University Children's Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Preterm infants < 37 weeks.
- Stable on nasal continuous positive airway pressure (CPAP) for at least 24 hours.
- On less than 35% oxygen.
Exclusion Criteria:
- Congenital and acquired problems of the gastrointestinal tract as necrotizing enterocolitis, esophageal perforation and tracheoesophageal fistula.
- Phrenic nerve injury and/or diaphragm paralysis
- Congenital/acquired neurological deficit and/or seizures
- Hemodynamic instability
- Congenital heart disease (including symptomatic patent ductus arteriosus)
- Undergoing treatment for sepsis or pneumonia.
- Use of muscle relaxants, narcotic analgesics, or gastric motility agents.
- Congenital anomalies of respiratory tract.
- Infants requiring more than 35% oxygen.
- Infants with facial anomalies.
- Infants with pneumothorax and/or pneumomediatinum.
- Infants in the immediate postoperative period.
- Infants with significant gastric residues and vomiting.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: CPAP first
Infant will be given nasal CPAP for 60 minutes and then put on HHHFNC for another 60 minutes.
Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of the 60 minute periods on nasal CPAP and HHHFNC.
After the 2 h study period (2×60 minutes epochs) further respiratory support will be at the discretion of the clinical team
|
Infants will start on nasal CPAP for 60 minutes and then switched to HHHFNC for anther 60 minutes.
Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
|
|
Comparateur actif: HHHFNC first
Infant will be given HHHFNC for 60 minutes and then switched to nasal CPAP for another 30 minutes.
Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of the 60 minute periods on HHHFNC and nasal CPAP.
After the 2 h study period (2×60 minutes epochs) further respiratory support will be at the discretion of the clinical team
|
Infants will start on HHHFNC for 60 minutes and then switched to nasal CPAP for anther 60 minutes.
Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Diaphragmatic dimensions (inspiratory diaphragmatic thickness, expiratory diaphragmatic thickness and delta diaphragmatic thickness)
Délai: at the end of each 60 minutes epoch on nasal CPAP
|
Ultrasonographic assessment of (inspiratory diaphragmatic thickness, expiratory diaphragmatic thickness and delta diaphragmatic thickness will be assessed at the end of each 60 minutes epoch on nasal CPAP.
Diaphragm thickness will be measured as the perpendicular distance between the pleural and peritoneal reflections.
All measurements will be performed during quiet breathing.
Several respiratory cycles will be recorded, and measurements will be averaged from at least three different cycles.
|
at the end of each 60 minutes epoch on nasal CPAP
|
|
Right and left diaphragmatic excursion
Délai: at the end of each 60 minute epoch on CPAP
|
Ultrasonographic assessment of right and left diaphragmatic excursion will be assessed at the end of each 60 minutes epoch on nasal CPAP.
The displacements of the liver and spleen will be monitored in real-time.
Using M-mode ultrasonography, with the probe fixed on the chest wall during respiration, ultrasonographic image of will be frozen and a mark for measurement will be placed on the image at the location of the most caudal margin of the liver or spleen at the end of expiration, and a second mark will be placed on the new location of the most caudal margin of the liver or spleen at the end of inspiration.
The distance between the two marks will be then measured and defined as the displacement of the liver or the spleen (right or left diaphragmatic excursion).
Several respiratory cycles will be recorded, and measurements will be averaged from at least three different cycles.
|
at the end of each 60 minute epoch on CPAP
|
|
Diaphragmatic dimensions (inspiratory diaphragmatic thickness, expiratory diaphragmatic thickness and delta diaphragmatic thickness)
Délai: at the end of each 60 minutes epochs on HHHNC
|
Ultrasonographic assessment of (inspiratory diaphragmatic thickness, expiratory diaphragmatic thickness and delta diaphragmatic thickness will be assessed at the end of each 60 minutes epoch on HHHFNC.
Diaphragm thickness will be measured as the perpendicular distance between the pleural and peritoneal reflections.
All measurements will be performed during quiet breathing.
Several respiratory cycles will be recorded, and measurements will be averaged from at least three different cycles.
|
at the end of each 60 minutes epochs on HHHNC
|
|
Right and left diaphragmatic excursion
Délai: at the end of each 60 minutes epochs on HHHNC
|
Ultrasonographic assessment of right and left diaphragmatic excursion will be assessed at the end of each 60 minutes epoch on HHHFNC.
The displacements of the liver and spleen will be monitored in real-time.
Using M-mode ultrasonography, with the probe fixed on the chest wall during respiration, ultrasonographic image of will be frozen and a mark for measurement will be placed on the image at the location of the most caudal margin of the liver or spleen at the end of expiration, and a second mark will be placed on the new location of the most caudal margin of the liver or spleen at the end of inspiration.
The distance between the two marks will be then measured and defined as the displacement of the liver or the spleen (right or left diaphragmatic excursion).
Several respiratory cycles will be recorded, and measurements will be averaged from at least three different cycles.
|
at the end of each 60 minutes epochs on HHHNC
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Respiratory rate
Délai: At the end of each 60 minutes epochs on CPAP and HHHFNC
|
Respiratory rate will be assessed at the end of each 60 minutes epoch on CPAP or HHHFNC
|
At the end of each 60 minutes epochs on CPAP and HHHFNC
|
|
Heart rate
Délai: At the end of each 60 minutes epochs on CPAP and HHHFNC
|
Heart rate will be assessed at the end of each 60 minutes epoch on CPAP or HHHFNC
|
At the end of each 60 minutes epochs on CPAP and HHHFNC
|
|
Spo2
Délai: At the end of each 60 minutes epochs on CPAP and HHHFNC
|
Oxygen saturation by pulse oximetry (SpO2) will be assessed at the end of each 60 minutes epoch on CPAP or HHHFNC
|
At the end of each 60 minutes epochs on CPAP and HHHFNC
|
|
Number of apneas
Délai: during the 60 minutes epochs on CPAP and HHHFNC
|
Number of apneas will be recorded during the 60 minutes epoch on CPAP or HHHFNC
|
during the 60 minutes epochs on CPAP and HHHFNC
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- MS 874
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur CPAP first (Fisher & Paykel Healthcare)
-
Fisher and Paykel HealthcareComplété
-
Fisher and Paykel HealthcareComplété
-
Fisher and Paykel HealthcareComplété
-
Associação Fundo de Incentivo à PesquisaFisher and Paykel Healthcare; Philips RespironicsInconnue
-
All India Institute of Medical Sciences, New DelhiComplétéÉchec de l'extubationInde
-
Changi General HospitalComplété
-
Johns Hopkins UniversityUniversity of North Carolina, Chapel Hill; Children's Hospital Medical Center... et autres collaborateursRésiliéPneumonie | Malnutrition | Hypoxémie | Virus de l'immunodéficience humaine (VIH)Malawi